Heron Therapeutics reported modest second-quarter revenue growth, but uncertainty around potential generic CINVANTI competition and a strategic alternatives process prompted the company to withdraw its full-year 2026 guidance.
Key Investor Takeaways
- Heron Therapeutics (NASDAQ:HRTX) reported Q2 2026 total net revenue of $37.7 million, up 1.3% year over year but below management’s expectations.
- Acute Care revenue increased 43.9%, led by ZYNRELEF and APONVIE, while Oncology revenue fell 15.9%.
- The company withdrew its 2026 net product sales and Adjusted EBITDA guidance following a June court decision affecting CINVANTI patents, uncertainty over generic entry and changes to its commercial spending plan.
- HRTX is also considering strategic alternatives, although management said there is no timetable and no assurance that the process will result in a transaction.
- Heron ended the quarter with $42.7 million in cash, cash equivalents and short-term investments after what management described as a balance-sheet reset and tighter spending.
Why HRTX Stock Is in Focus
Heron Therapeutics (NASDAQ:HRTX) withdrew its full-year 2026 guidance after second-quarter revenue came in below internal expectations and uncertainty increased around its largest product, CINVANTI.
Total net revenue reached $37.7 million, up 1.3% from $37.2 million a year earlier.
Performance diverged sharply between the company’s franchises. Acute Care revenue increased 43.9% to $15.3 million, with ZYNRELEF revenue rising 35.0% to $11.1 million and APONVIE increasing 73.6% to $4.3 million.
Oncology revenue declined 15.9% to $22.3 million. CINVANTI revenue fell 9.7% to $21.8 million, while SUSTOL revenue dropped 77.5% to $0.5 million.
For the first six months of 2026, total revenue declined 4.9% to $72.4 million, reflecting 38.2% growth in Acute Care but a 21.3% decline in Oncology.
Why This Matters for Investors
The withdrawal of guidance materially increases uncertainty around Heron’s near-term financial outlook.
Management cited three reasons for the decision. First, a June 2026 U.S. District Court ruling involving certain CINVANTI patents has made it difficult for the company to forecast the timing or terms of potential generic competition.
That matters because CINVANTI remains Heron’s largest product, generating $21.8 million of the company’s $37.7 million in Q2 revenue.
Second, Heron paused the sales force expansion that had been included in its previous second-half operating plan and is tightening spending. That could help preserve cash, but it also changes the commercial assumptions underlying the company’s prior guidance.
Third, Heron is evaluating strategic alternatives while continuing to execute its existing plan. The company has not set a timetable and cautioned that the review may not result in any transaction.
The contrast between the two franchises is also important. Rapid growth in ZYNRELEF and APONVIE suggests Acute Care is gaining momentum, but that growth has not yet been enough to offset deterioration in the larger Oncology business.
What to Watch Next
The most immediate issue is potential generic entry for CINVANTI and any further developments related to the patent litigation.
Investors may also watch whether continued growth in ZYNRELEF and APONVIE can offset declining Oncology revenue, particularly if CINVANTI faces additional competitive pressure.
Updates from the strategic alternatives process, changes in operating expenses and the company’s ability to preserve its $42.7 million cash position could also become increasingly important as Heron operates without formal 2026 financial guidance.